Literature DB >> 17198396

Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 1. A new strategy for generation of anti-carbohydrate antibodies.

Keiko Sakai1, Yoshitaka Shimizu, Tomoki Chiba, Ayano Matsumoto-Takasaki, Yu Kusada, Wei Zhang, Munehiro Nakata, Naoya Kojima, Kazunori Toma, Atsushi Takayanagi, Nobuyoshi Shimizu, Yoko Fujita-Yamaguchi.   

Abstract

Phage-display technology is probably the best available strategy to produce antibodies directed against various carbohydrate moieties since conventional hybridoma technologies have yielded mostly low-affinity antibodies against a limited number of carbohydrate antigens. Because of difficulties in immobilization of carbohydrate antigens onto plastic plates, however, the same procedures used for protein antigens cannot be readily applied. We adapted phage-display technology to generate human single chain antibodies (scFvs) using neoglycolipids as antigens. This study describes the isolation and characterization of phage-displayed antibodies (phage Abs) that recognized nonreducing terminal mannose residues. We first constructed a phage Ab library with a large repertoire using CDR shuffling and VL/VH shuffling methods with unique vector constructs. The library was subjected to four rounds of panning against neoglycolipids synthesized from mannotriose (Man3) and dipalmitoylphosphatidylethanolamine (DPPE) by reductive amination. Of 672 clones screened by enzyme-linked immunosorbent assay (ELISA) using Man3-DPPE as an antigen, 25 positive clones encoding scFvs with unique amino acid sequences were isolated as candidates for phage Abs against Man3 residues. TLC-overlay assays and surface plasmon resonance analyses revealed that selected phage Abs bound to neoglycolipids bearing mannose residues at nonreducing termini. In addition, binding of the phage Ab to RNase B carrying high mannose type oligosaccharides but not to fetuin carrying complex type and O-linked oligosaccharides was confirmed. Furthermore, first round characterization of scFvs expressed from respective phages indicated good affinity and specificity for nonreducing terminal mannose residues. These results demonstrated the usefulness of this strategy in constructing human scFv against various carbohydrate antigens. Further studies on the purification and characterization of these scFvs are presented in an accompanying paper in this issue.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17198396     DOI: 10.1021/bi061875e

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

Review 1.  Peptide-displaying phage technology in glycobiology.

Authors:  Michiko N Fukuda
Journal:  Glycobiology       Date:  2011-09-19       Impact factor: 4.313

2.  Metal Nanoshell - Capsule for Light-Driven Release of Small Molecule.

Authors:  Jian Zhang; Yi Fu; Feng Jiang; Joseph R Lakowicz
Journal:  J Phys Chem C Nanomater Interfaces       Date:  2010-04-02       Impact factor: 4.126

3.  Production of anti-carbohydrate antibodies by phage display technologies: potential impairment of cell growth as a result of endogenous expression.

Authors:  Noriyuki Yuasa; Wei Zhang; Tomohiro Goto; Hiroyuki Sakaue; Ayano Matsumoto-Takasaki; Miyo Kimura; Hiroya Ohshima; Yasunobu Tsuchida; Tomoyuki Koizumi; Keiko Sakai; Takumi Kojima; Kazuo Yamamoto; Munehiro Nakata; Yoko Fujita-Yamaguchi
Journal:  J Biol Chem       Date:  2010-07-28       Impact factor: 5.157

4.  Antibody-based sensors: principles, problems and potential for detection of pathogens and associated toxins.

Authors:  Barry Byrne; Edwina Stack; Niamh Gilmartin; Richard O'Kennedy
Journal:  Sensors (Basel)       Date:  2009-06-05       Impact factor: 3.576

Review 5.  scFv antibody: principles and clinical application.

Authors:  Zuhaida Asra Ahmad; Swee Keong Yeap; Abdul Manaf Ali; Wan Yong Ho; Noorjahan Banu Mohamed Alitheen; Muhajir Hamid
Journal:  Clin Dev Immunol       Date:  2012-03-15

6.  A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.

Authors:  Hiroko Ishii; Maram H Zahra; Atushi Takayanagi; Masaharu Seno
Journal:  Int J Mol Sci       Date:  2021-02-08       Impact factor: 5.923

Review 7.  Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective.

Authors:  Hamideh Raeisi; Masoumeh Azimirad; Ali Nabavi-Rad; Hamid Asadzadeh Aghdaei; Abbas Yadegar; Mohammad Reza Zali
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

Review 8.  Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy.

Authors:  Paola Muñoz-López; Rosa María Ribas-Aparicio; Elayne Irene Becerra-Báez; Karla Fraga-Pérez; Luis Fernando Flores-Martínez; Armando Alfredo Mateos-Chávez; Rosendo Luria-Pérez
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

9.  Production of a recombinant antibody specific for i blood group antigen, a mesenchymal stem cell marker.

Authors:  Tia Hirvonen; Heli Suila; Sari Tiitinen; Suvi Natunen; Marja-Leena Laukkanen; Annika Kotovuori; Mirka Reinman; Tero Satomaa; Kaija Alfthan; Saara Laitinen; Kristiina Takkinen; Jarkko Räbinä; Leena Valmu
Journal:  Biores Open Access       Date:  2013-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.